Home
Halozyme Therapeutics HALO paid Forbes-Tate $20K for lobbying in Q2 2023 · Medicare
Trade details
- Type
- Lobbying report
- Amount
- $20,000
- Quarter
- Q2 2023
- Client
- Halozyme Therapeutics
- Reported
- 23/07/16
$20K on lobbying this year
What else happened in Halozyme Therapeutics around then
Filed or reported within 30 days of the trade day · 23/05/31~23/07/30Halozyme Therapeutics's other lobbying reports
- Halozyme Therapeutics
LobbyingHalozyme Therapeutics
LobbyingHalozyme Therapeutics
HALO
$80K
$80K
Reported 07/20
for Q2
- Halozyme Therapeutics
LobbyingHalozyme Therapeutics
LobbyingHalozyme Therapeutics
HALO
$70K
$70K
Reported 04/18
for Q1
- Halozyme Therapeutics
LobbyingHalozyme Therapeutics
LobbyingHalozyme Therapeutics
HALO
$60K
$60K
Reported 01/18
for Q4 2025
- Halozyme Therapeutics
LobbyingHalozyme Therapeutics
LobbyingHalozyme Therapeutics
HALO
$60K
$60K
Reported 25/10/18
for Q3 2025
- Halozyme Therapeutics
LobbyingHalozyme Therapeutics
LobbyingHalozyme Therapeutics
HALO
$60K
$60K
Reported 25/07/18
for Q2 2025